Rxsight Co-Präsident Ilya Goldshleger acquires Aktien at a value of US$309,850 from Investing.com

Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc. (NASDAQ:RXST), has executed trading transactions with Unternehmens stock brokers. The US-Börsenaufsicht SEC-verkaufte Goldshleger Aktien has been actively reported in the deal for an amount of US-Dollar 309,850. Sales started between October 16 and 18, with prices ranging from US$49.7799 to US$50.59 pro-action.

The Goldshleger paid a close price during the purchase of Aktienoptions and a purchase amount of 6,205 Aktien for a jewelry auction of 15.08 US dollars. After the trades were executed by Goldshleger, they were previously processed by 42.246 Aktien and RxSight, Inc.

The purchases are made in accordance with the rules laid down in accordance with Rule 10b5-1. Solche Planen ermöglichen es Unternehmensinsidern, een vorbestimmten Plan voor de Verkauf von Aktien aufzustellen, a reservations regarding Insiderhandels should be avoided.

In others, RxSight Inc. reported 68% quarter 2024 results of US$34.9 million received from misselling Light Adjustable Lens (LAL) and Light Delivery Devices (LDDs). The analysis of expectations for the US dollar in 2024 is high. The analysts at BTIG and Needham have used their Kaufempfehlungen for RxSight, which sees a quarter of the forecasts of US$37 and US$38 million. After RxSight was approved by the FDA for a study on the effectiveness of the LAL+, the commercial publication was published in late 2024. Trotz Herausforderungen in verschiedenen europäischen Markten ist RxSight bestrebt, seine international regulators Zulassungen auszuweiten.

InvestingPro Acknowledgment

An Ilya Goldshlegers has brought with her the most active transactions in a knitting context, bringing some important financial knowledge and experience to RxSight, Inc. (NASDAQ:RXST) is involved.

Laut InvestingPro-Daten that RxSight had a market capitalization of US$1.99 million, the companies were positioned as Mid-Cap companies in the financial sector. The developing world has adopted austerity policies, with a value of 71.9% in the last month of the month of which it has earned an amount of US$115.18 million in the 2024 quarter. This strong enterprise of the Einnahmen is in the Einklang with the young Aktienkursentwicklung of the Unternehmens, which shows the trend of 98.77% over time.

The strong returns on RxSight are not profitable, with a negative impact of US$42.37 million in the last month of the month. The reflection of the negative Kurs-Gewinn-Verhältnis (KGV) of -56.32 was broader, but the Investors of the Unternehmen had started to buy Wachstum saucesichten on the Basis as on the Basis-aktueller Gewin bewerten.

An InvestingPro-Tipp has previously, when RxSight had more Barmittel as debt in its Bilanz stop, was a positive point for the financial stability of the Unternehmens. This strong liquidity position can increase the company’s flexibility, an initiative that invests in or potential market value in the future.

Another InvestingPro tip was that RxSight’s liquid assets were the most effective sales transactions, the Unternehmens’ solid financial foundation continued later. This smart Bilanz can ensure that investors are impressed by the young Insider transactions.

If you analyze any of the following, you can give InvestingPro 8 other tips for RxSight, which offers one of the financial opportunities and market position of our external economies.

The article is found at www.tipranks.com.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.